Chemical Component Summary

Name2'-DEOXYCOFORMYCIN
Identifiers(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-6H-imidazo[4,5-f][1,3]diazepin-8-ol
FormulaC11 H16 N4 O4
Molecular Weight268.27
TypeNON-POLYMER
Isomeric SMILESOC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12
InChIInChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1
InChIKeyFPVKHBSQESCIEP-JQCXWYLXSA-N

Chemical Details

Formal Charge0
Atom Count35
Chiral Atom Count4
Chiral AtomsC1S, C3S, C4S, C8
Bond Count37
Aromatic Bond Count5
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00552 Different stereochemistry
NamePentostatin
Groups
  • approved
  • investigational
DescriptionA potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. [PubChem]
Synonyms
  • Co-vidarabine
  • Nipent
  • Pentostatin
  • Pentostatina
  • Pentostatine
Brand Names
  • Nipent
  • Nipent Pws 10mg/vial
Affected Organism
  • Humans and other mammals
  • Mycobacterium tuberculosis
  • Pseudomonas aeruginosa
  • Leptospira interrogans
  • Borrelia burgdorferi
IndicationFor the treatment of hairy cell leukaemia refractory to alpha interferon.
PharmacologyPentostatin is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute nonlymphocytic leukemia and hairy cell leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. It is a 6-thiopurine analogue of the naturally occurring purine bases hypoxanthine and guanine. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Cytotoxicity is cell cycle phase-specific (S-phase).
Mechanism of actionPentostatin is a potent transition state inhibitor of adenosine deaminase (ADA), the greatest activity of which is found in cells of the lymphoid system. T-cells have higher ADA activity than B-cells, and T-cell malignancies have higher activity than B-cell malignancies. The cytotoxicity that results from prevention of catabolism of adenosine or deoxyadenosine is thought to be due to elevated intracellular levels of dATP, which can block DNA synthesis through inhibition of ribonucleotide reductase. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Cytotoxicity is cell cycle phase-specific (S-phase).
Route of administrationIntravenous
Categories
  • Adenosine Deaminase Inhibitors
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Carbohydrates
  • Chemical Actions and Uses
ATC-CodeL01XX08
CAS number53910-25-1

Drug Targets

NameSequence SearchPharmacological ActionActions
Adenosine deaminaseMAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVI...yesinhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682